As of today, here are some therapeutic compounds approved by the Food and Drug Administration (FDA) whose mechanism of action involves inhibiting components of the MAPK/ERK cascade, such as trametinib, a MEK inhibitor used for metastatic melanoma [22]. The gene discussed is MAPK1; the disease is metastatic melanoma.